SNY Stock Analysis: Buy, Sell, or Hold?
SNY - Sanofi American Depositary Shares (Each representing one-half of one ordinary share)
$42.74
0.32 (0.75%)
▲
5d:
-1.02%
30d:
-11.0%
90d:
-9.12%
HOLD
MODERATE Confidence
Analysis Updated: May 13, 2026 12:00 AM ET
Earnings: Apr 23, 2026
0d
Get Alerted When SNY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
2 traders called SNY this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: SNY shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: SNY shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$61.46
Based on 5.9% avg growth
INTRINSIC VALUE TODAY
$38.16
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 8.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SNY is currently trading at $42.74, which is considered oversold relative to its 30-day fair value range of $43.85 to $47.74. The stock's valuation (Forward PE: 8.2) is in line with its historical norms (8.9). Remarkably, the market is currently pricing in an annual earnings decline of 2.8% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, SNY is in a downtrend. The price is currently testing key support at $42.33. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SNY has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $55.90 (+31.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, SNY is in a downtrend. The price is currently testing key support at $42.33. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SNY has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $55.90 (+31.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$43.85 -
$47.74
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 31.8% below Wall St target ($55.90)
Trading Range Analysis
30-Day Trading Range
$43.85 -
$47.74
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$42.33
Resistance Level
$46.98
Current Trend
Downtrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
8.18
Wall Street Target
$55.90
(+31.8%)
Revenue Growth (YoY)
6.0%
Earnings Growth (YoY)
-11.7%
Profit Margin
16.0%
Valuation Discount vs History
-2.8% cheaper
PE vs Historical
8.2 vs 8.9
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.8%
(market-implied from PE analysis)
1-Year Target
$41.23
(-3%)
2-Year Target
$40.08
(-6%)
3-Year Target
$38.96
(-8%)
3-Yr Target (if PE normalizes)
(PE: 8→9)
$42.39
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.0, Growth: 7.8%)
$143.18
(+238%)
Base:
(SPY PE: 8.2, Growth: 7.8%)
$53.13
(+25%)
Bear:
(PE: 7.0, Growth: 7.8%)
$45.16
(+7%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (18x PE), but valuation improves significantly next year (8x PE) as earnings recover.
Trailing PE: 18.24 | Current EPS (TTM): $2.33
Bull Case
$93.50
(+120%)
Analyst growth 100.0%, PE expands to 20.1
Base Case
$85.00
(+100%)
Market implied 100.0%, PE stable at 18.2
Bear Case
$28.90
(-32%)
Severe decline -20.0%, PE contracts to 15.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 8.2 to 8.9
Stabilization Target:
$46.16
(+8.8%)
PE Expansion Potential:
+8.8%
Share & Embed Analysis
Last updated: May 14, 2026 12:45 PM ET
Data refreshes hourly during market hours. Next update: 1:45 PM
Data refreshes hourly during market hours. Next update: 1:45 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SNY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
29 analysts |
$1209 | 61 BUY |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$158 | 59 HOLD |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$252 | 63 BUY |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$217 | 64 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$353 | 58 HOLD |
